Evolving Treatments Seek to Address Unanswered Questions in Hematologic Malignancies
November 16th 2022Novel agents such as momelotinib and pacritinib are expanding the myelofibrosis treatment landscape, and additional research will further define the options available for patients with this disease, as well as those with other leukemias and lymphomas.
Read More
CAR T-cell Coadministration Strengthens Responses in Childhood B-cell ALL
November 15th 2022The coadministration of CD19 and CD22 CAR T-cell therapy elicited promising responses and event-free survival rates in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to findings from a phase 2 trial.
Read More
Multidisciplinary Discussions Shape Systemic and Surgical Skin Cancer Treatment
November 15th 2022Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery.
Read More
Deep Responses Demonstrate Association With Prolonged Survival to Nivolumab/Cabozantinib in mRCC
November 4th 2022Patients with treatment-naïve advanced renal cell carcinoma who received nivolumab plus cabozantinib achieved deeper objective responses leading to improved progression-free survival and overall survival rates vs those who received sunitinib, according to exploratory data from the CheckMate 9ER trial.
Read More
Novel Trial Designs and Modern Research Efforts Drive RCC Treatment Advances
November 4th 2022Eric Jonasch, MD, discusses key clinical trials that are paving the way for improved treatment sequencing in renal cell carcinoma and the prospective benefits of neoadjuvant cabozantinib in nonmetastatic clear cell renal cell carcinoma.
Read More
Targeted Therapies and Expanded NGS Access Improve Decision Making in Lung Cancer
November 3rd 2022Melissa L. Johnson, MD, shares key insights from the meeting, including pertinent findings in KRAS G12C¬–mutated NSCLC from the phase 3 CodeBreak 200 study and positive findings with atezolizumab in platinum-ineligible patients with NSCLC.
Read More
Targeting E-Selectin With Uproleselan Confers Potential Efficacy and Safety Benefits in AML
November 3rd 2022Uproleselan, an agent that disrupts the interaction between leukemia cells and their protective E-selectin microenvironment, is a promising novel AML therapy that may increase the efficacy and durability of other AML treatments.
Read More
BCMA and CD3 T-cell–Engaging Bispecific Antibody Shows Promise in R/R Multiple Myeloma
November 1st 2022ABBV-383 was effective and well tolerated at all administered doses in patients with relapsed/refractory multiple myeloma, according to safety and efficacy results from an ongoing first-in-human, phase 1 dose-escalation/-expansion study.
Read More
Darolutamide Combination Improves OS vs Placebo in Black Patients With mHSPC
October 28th 2022Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.
Read More
Carefully selected patients with triple-negative or HER2-positive breast cancer who demonstrated pathologic complete responses to neoadjuvant systemic therapy as predicted by image-guided vacuum-assisted core biopsy avoided breast surgery and went on to standard radiotherapy.
Read More
Chemoimmunotherapy Combo Elicits Encouraging Responses in Relapsed High-Risk Neuroblastoma
October 25th 2022The 4-drug combination of irinotecan, temozolomide, dinutuximab, and granulocyte-macrophage colony-stimulating factor elicited objective responses in almost half of patients with high-risk neuroblastoma.
Read More
Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer
October 24th 2022The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.
Read More
E-selectin Inhibitor Uproleselan May Bolster SOC Efficacy in AML
October 20th 2022Richard M. Stone, MD, highlights how uproleselan disrupts E-selectin in the AML tumor microenvironment, the variety of AML regimens that uproleselan may amplify in efficacy, including chemotherapies and venetoclax combinations, and the need for further research to determine whether minimal residual disease negativity rates will improve patient prognoses.
Read More
Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL
October 20th 2022Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.
Read More
Novel Treatments Begin to Rival Transplant in AML and DLBCL
October 18th 2022Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.
Read More
Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
October 18th 2022Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.
Read More
Novel ADC and CAR T Approaches Broaden the DLBCL Treatment Landscape
October 17th 2022Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.
Read More
Proteosome Inhibitors Plus CD38 Antibodies Elicit Encouraging Responses in Multiple Myeloma
October 15th 2022Peter Voorhees, MD, discusses key points from his presentation on proteasome inhibitors in multiple myeloma and positive data with the agents in the transplant-eligible and transplant-ineligible populations.
Read More
Standards of Care Shift Toward Patient Specificities in Bladder and Prostate Cancers
October 13th 2022Shilpa Gupta, MD, discussed potential therapies for patients with cisplatin-ineligible metastatic urothelial carcinoma, the benefits of sacituzumab govitecan and erdafitinib in later-line urothelial carcinoma, and treatment options for nonmetastatic castration-resistant prostate cancer.
Read More
Increasingly Sensitive Genetic Testing Advances GI Cancer Diagnosis and Management
October 8th 2022John Lindsay Marshall, MD, discusses past, present, and future developments in molecular testing, as well as the unique offerings of tissue and blood tests and the ways in which these precise approaches will ultimately make cancer diagnosis and treatment more efficient and effective.
Read More
Efforts Underway to Generate Real-World Evidence for Second-line Strategies in SCLC
October 7th 2022Nicolas Girard, MD, PhD, highlights current treatment practices, the value real-world data would provide for future investigative approaches in SCLC, and the observed benefit of administering available treatment options such as lurbinectedin as early as possible.
Read More
Ivosidenib/Venetoclax/Azacitidine Proves Tolerable, Strengthens Survival in AML
October 6th 2022Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.
Read More
ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML
October 5th 2022Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.
Read More
Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL
October 4th 2022Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .
Read More
E-Selectin Upregulation and Chemo Combinations Among Recent Developments in AML
September 29th 2022E-selectin has emerged as a viable target in acute myeloid leukemia, and agents like uproleselan have the potential the increase AML cells’ sensitivity to chemotherapies such as cladribine plus low-dose cytarabine.
Read More